{
    "root": "2f74965f-3c85-0590-e063-6294a90af267",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Ezetimibe and Simvastatin",
    "value": "20250303",
    "ingredients": [
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "ISOPROPYL ALCOHOL",
            "code": "ND2M416302"
        },
        {
            "name": "PROPYL GALLATE",
            "code": "8D4SNN7V92"
        },
        {
            "name": "BUTYLATED HYDROXYANISOLE",
            "code": "REK4960K2U"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "CITRIC ACID MONOHYDRATE",
            "code": "2968PHW8QP"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        },
        {
            "name": "EZETIMIBE",
            "code": "EOR26LQQ24"
        },
        {
            "name": "SIMVASTATIN",
            "code": "AGG2FN16EV"
        }
    ],
    "indications": "Ezetimibe and Simvastatin\n                  \n                  Ezetimibe and simvastatin is a combination of simvastatin and ezetimibe indicated:\n                  • As an adjunct to diet to reduce elevated low density lipoprotein cholesterol (LDL-C):\n                  o In adults with primary hyperlipidemia.\n                  o In adults and pediatric patients aged 10 years and older with\n                                 heterozygous familial hypercholesterolemia (HeFH).\n                  • As an adjunct to other LDL-C-lowering therapies to reduce elevated LDL-C in adults with homozygous familial hypercholesterolemia (HoFH).\n                  \n                     Simvastatin\n                  \n                  Simvastatin, when used as a component of ezetimibe and simvastatin, is indicated to reduce the risk of total mortality by reducing risk of coronary heart disease death, non-fatal myocardial infarction and stroke, and the need for coronary and non-coronary revascularization procedures in adults with established coronary heart disease, cerebrovascular disease, peripheral vascular disease, and/or diabetes, who are at high risk of coronary heart disease events.",
    "contraindications": "Important Dosage and Administration Information: (2.1) Take ezetimibe and simvastatin orally once daily in the evening with or without food. Maximum recommended dosage is ezetimibe and simvastatin 10/40 mg once daily. Ezetimibe and simvastatin 10/80 mg daily dosage is restricted to patients who have been taking ezetimibe and simvastatin 10/80 mg daily chronically (e.g., for 12 months or more) without evidence of muscle toxicity. For patients that require a high-intensity statin or are unable to achieve their LDL-C goal receiving ezetimibe and simvastatin 10/40 mg daily, prescribe alternative LDL-C-lowering treatment. If as dose is missed, take the missed dose as soon as possible. Do not double the next dose. Assess LDL-C when clinically appropriate, as early as 2 weeks after initiating ezetimibe and simvastatin, and adjust the dosage if necessary. Adults: Recommended dosage range of 10/10 mg to 10/40 mg once daily. (2.2) See full prescribing information for ezetimibe and simvastatin dosage modifications due to drug interactions. (2.3) Patients with Renal Impairment: Doses exceeding 10/20 mg should be used with caution and close monitoring in patients with moderate to severe renal impairment. (2.4)",
    "warningsAndPrecautions": "Ezetimibe and simvastatin tablets 10/40, (ezetimibe, USP 10 mg/simvastatin, USP 40 mg tablets) are white to off-white, capsule shaped tablets debossed with “A027” on one side and plain on other side.\n                  \n                  NDC: 70518-1955-00\n                  PACKAGING: 90 in 1 BOTTLE PLASTIC\n                  \n                  Storage\n                  Store at 20 to 25o C (68 to 77 oF). [See USP Controlled Room Temperature.] Keep container tightly closed.\n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions": "Ezetimibe and simvastatin tablets is contraindicated in the following conditions:\n                  \n                     Concomitant use of strong CYP3A4 inhibitors (select azole anti-fungals, macrolide antibiotics, anti­viral medications, and nefazodone)\n  \n   [see Drug Interactions (\n   \n    7.1)]\n  \n   .\n \n  \n                     Concomitant use of cyclosporine, danazol, or danazol\n  \n   [see Drug Interactions (\n   \n    7.1)]\n  \n   .\n \n  \n                     Acute liver failure or decompensated cirrhosis\n  \n   [see Warnings and Precautions (\n   \n    5.3)]\n  \n   .\n \n  \n                     Hypersensitivity to simvastatin, ezetimibe, or any excipients in ezetimibe and simvastatin tablets. Hypersensitivity reactions, including anaphylaxis, angioedema, and Stevens-Johnson syndrome, have been reported\n  \n   [see Adverse Reactions (\n   \n    6.2)]\n  \n   ."
}